

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 29, 2026

Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)



Company name: EIKEN CHEMICAL CO.,LTD.

Listing: Tokyo Stock Exchange

Securities code: 4549

URL: <https://www.eiken.co.jp>

Representative: Yuji Segawa

President & CEO

Inquiries: Tomohiro Kudo

Executive Officer

Telephone: +81-3-5846-3379

Scheduled date to file semi-annual securities report: November 10, 2026

Scheduled date to commence dividend payments: December 1, 2026

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended September 30, 2026	21,388	4.7	1,587	(8.2)	1,616	(6.6)	1,125	(62.2)
September 30, 2025	20,430	3.6	1,729	10.4	1,730	1.9	2,979	127.5

Note: Comprehensive income For the six months ended September 30, 2026: ¥ 1,096 million [(58.8) %]
For the six months ended September 30, 2025: ¥ 2,664 million [116.5 %]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended September 30, 2026	34.10	34.05
September 30, 2025	90.43	90.22

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of September 30, 2026	64,023	44,247	69.1	1,338.00
March 31, 2026	62,657	44,034	70.1	1,333.07

Reference: Equity

As of September 30, 2026: ¥ 44,228 million

As of March 31, 2026: ¥ 43,945 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	29.00	-	29.00	58.00
Fiscal year ending March 31, 2027	-	29.00			
Fiscal year ending March 31, 2027 (Forecast)			-	29.00	58.00

Note: Revisions to the forecast of cash dividends most recently announced: None

Note: Breakdown of the second quarter dividend for the fiscal year ending March 31, 2027 :

Commemorative dividend - yen
Special dividend - yen

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	42,000	0.2	3,070	5.2	2,900	2.0	2,070	(44.2)	62.62

Note: Revisions to the financial result forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies()
Excluded: - companies()

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2026	34,541,438 shares
As of March 31, 2026	34,541,438 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2026	1,485,822 shares
As of March 31, 2026	1,575,865 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2026	33,003,121 shares
Six months ended September 30, 2025	32,952,939 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

Table of Contents - Attachments

1. Overview of Consolidated Business Performance	2
(1) Summary of Consolidated Business Performance for Semi-annual of The Current Fiscal Year	2
(2) Summary of Consolidated Financial Position for Semi-annual of The Current Fiscal Year	2
(3) Semi-annual Information Regarding Forecasts for Consolidated Business Performance	3
2. Semi-annual Consolidated Financial Statements and Primary Notes	4
(1) Semi-annual Consolidated Balance Sheet	4
(2) Semi-annual Consolidated Statements of Income and Comprehensive Income	6
Semi-annual Consolidated Statements of Income	6
Semi-annual Consolidated Statements of Comprehensive Income	7
(3) Notes to Semi-annual Consolidated Financial Statements	8
(Notes on going concern assumption)	8
(Notes in case of significant changes in shareholders' equity)	8
(Accounting methods adopted particularly for the preparation of semi-annual consolidated financial statements)	8

1. Overview of Consolidated Business Performance

(1) Summary of Consolidated Business Performance for Semi-annual of The Current Fiscal Year

During the semi-annual of the current consolidated fiscal period, the domestic and overseas economies remained unstable due to the effects of surging resource prices and geopolitical risks.

The business environment became increasingly severe in the clinical diagnostics industry due to measures to cap medical expenses and rising costs such as for logistics and raw material procurement, on account of yen depreciation and high crude oil prices. Corporations were obliged to focus on cost competitiveness and to strategically expand overseas.

In the context of this business environment, the Eiken Group is implementing key measures focused on the three key business fields of “Contribution to cancer prevention and treatment,” “Contribution to the eradication and control of infectious diseases,” and “Provision of products and services useful for health care,” while also advancing fundamental reforms aimed at strengthening the Group’s overall earnings base, in accordance with the Management Plan 2030. In addition, as a Group with a mission to protect the health of people worldwide, the Eiken Group is addressing issues not only in “Medical,” but also in “Environment,” “Society,” and “Governance.” Through these efforts, we strive to further enhance our corporate value and achieve a sustainable society.

Net sales for the semi-annual of the current consolidated fiscal period increased to 21,388 million yen (up 4.7% year-on-year) due to strong growth in sales of fecal immunochemical test reagents and tuberculosis genetic testing reagents for overseas markets, and medical devices for domestic markets. For net sales by product class and type, sales of microbiological testing reagents were 2,141 million yen (down 0.3% year-on-year). Sales of urinalysis reagents were 2,288 million yen (down 3.1% year-on-year). Sales of immunological and serological reagents were 12,287 million yen (up 4.6% year-on-year) due to strong sales of fecal immunochemical test reagents for overseas markets. Sales of clinical chemistry reagents were 289 million yen (down 3.6% year-on-year), and sales of the equipment and culture medium for food and environment related category were 800 million yen (down 15.8% year-on-year). Sales in other categories (medical devices, genetic-related products, etc.) were 3,581 million yen (up 22.5% year-on-year), despite sluggish sales of genetic-related products in domestic markets and the impact of temporary patent royalty income recorded in the same period of the previous fiscal year, due to increased sales of medical devices for domestic markets and growth in sales of tuberculosis genetic testing reagents for overseas markets. Overseas sales were 6,137 million yen (up 12.6% year-on-year) amid an increase in sales of fecal immunochemical test reagents and tuberculosis genetic testing reagents.

Regarding profit, although net sales increased, operating profit was 1,587 million yen (down 8.2% year-on-year), ordinary profit was 1,616 million yen (down 6.6% year-on-year), reflecting the impact of temporary patent royalty income recorded in the same period of the previous fiscal year and changes in the sales mix. Profit attributable to owners of parent was 1,125 million yen (down 62.2% year-on-year), reflecting the impact of the one-time extraordinary income from the transfer of equity interests in a consolidated subsidiary recorded in the same period of the previous fiscal year.

(2) Summary of Consolidated Financial Position for Semi-annual of The Current Fiscal Year

The financial position at the end of the semi-annual of the current consolidated fiscal period was as follows.

Compared to the end of the previous consolidated fiscal year, total assets increased by 1,366 million yen, liabilities increased by 1,153 million yen, and net assets increased by 212 million yen.

Major increases and decreases in the category of assets were an increase of 1,700 million yen in cash and deposits, an increase of 1,540 million yen in electronically recorded monetary claims - operating, and a decrease of 1,013 million yen in notes and accounts receivable - trade, and contract assets. Property plant and equipment decreased by 913 million yen. In the category of liabilities, electronically recorded obligations - operating increased by 958 million yen. In the category of net assets, although there were payments of dividends, shareholders’ equity increased by 311 million yen due to the recording of profit attributable to owners of parent.

As a result, the equity ratio decreased from 70.1% at the end of the previous consolidated fiscal year to 69.1%.

(3) Semi-annual Information Regarding Forecasts for Consolidated Business Performance

For the consolidated financial results forecast for the fiscal year ending March 31, 2027, there has been no change from the financial forecast announced on May 12, 2026.

2.Semi-annual Consolidated Financial Statements and Primary Notes

(1)Semi-annual Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	10,943	12,644
Notes and accounts receivable - trade, and contract assets	10,174	9,160
Electronically recorded monetary claims - operating	1,225	2,766
Merchandise and finished goods	4,354	4,285
Work in process	2,024	2,092
Raw materials and supplies	1,613	1,787
Other	1,710	1,395
Allowance for doubtful accounts	(6)	-
Total current assets	32,040	34,133
Non-current assets		
Property, plant and equipment		
Buildings and structures	32,206	32,258
Accumulated depreciation	(14,721)	(15,272)
Buildings and structures, net	17,484	16,985
Machinery, equipment and vehicles	8,735	8,983
Accumulated depreciation	(6,746)	(7,040)
Machinery, equipment and vehicles, net	1,989	1,942
Tools, furniture and fixtures	6,064	6,376
Accumulated depreciation	(5,103)	(5,301)
Tools, furniture and fixtures, net	960	1,075
Land	1,928	1,928
Leased assets	368	380
Accumulated depreciation	(161)	(132)
Leased assets, net	206	248
Construction in progress	767	243
Total property, plant and equipment	23,338	22,424
Intangible assets	332	298
Investments and other assets		
Long-term time deposits	1,200	1,300
Other	5,769	5,887
Allowance for doubtful accounts	(23)	(20)
Total investments and other assets	6,945	7,167
Total non-current assets	30,616	29,890
Total assets	62,657	64,023

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	4,838	5,383
Electronically recorded obligations - operating	2,622	3,580
Current portion of bonds payable	3,000	3,000
Current portion of long-term borrowings	300	300
Income taxes payable	708	582
Provision for bonuses	693	716
Other	2,473	2,278
Total current liabilities	14,636	15,840
Non-current liabilities		
Asset retirement obligations	65	64
Long-term borrowings	2,650	2,500
Other	1,271	1,371
Total non-current liabilities	3,986	3,936
Total liabilities	18,622	19,776
Net assets		
Shareholders' equity		
Share capital	6,897	6,897
Capital surplus	7,892	7,906
Retained earnings	30,884	31,054
Treasury shares	(2,242)	(2,114)
Total shareholders' equity	43,432	43,744
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	25	30
Foreign currency translation adjustment	7	6
Remeasurements of defined benefit plans	480	446
Total accumulated other comprehensive income	513	484
Share acquisition rights	89	18
Total net assets	44,034	44,247
Total liabilities and net assets	62,657	64,023

(2)Semi-annual Consolidated Statements of Income and Comprehensive Income

Semi-annual Consolidated Statement of Income

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Net sales	20,430	21,388
Cost of sales	12,059	13,298
Gross profit	8,371	8,089
Selling, general and administrative expenses	6,642	6,502
Operating profit	1,729	1,587
Non-operating income		
Interest income	8	9
Dividend income	4	15
Rental income	2	-
Compensation income	3	1
Subsidy income	27	77
Foreign exchange gains	2	-
Other	16	34
Total non-operating income	64	137
Non-operating expenses		
Interest expenses	9	39
Share of loss of entities accounted for using equity method	45	49
Foreign exchange losses	-	4
Other	8	15
Total non-operating expenses	63	108
Ordinary profit	1,730	1,616
Extraordinary income		
Gain on sale of non-current assets	0	1
Profit on transfer of capital investments in associated companies	2,004	-
Total extraordinary income	2,005	1
Extraordinary losses		
Loss on sale and retirement of non-current assets	6	0
Total extraordinary losses	6	0
Profit before income taxes	3,729	1,617
Income taxes	749	492
Profit	2,979	1,125
Profit attributable to non-controlling interests	-	-
Profit attributable to owners of parent	2,979	1,125

Semi-annual Consolidated Statement of Comprehensive Income

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Profit	2,979	1,125
Other comprehensive income		
Valuation difference on available-for-sale securities	44	5
Foreign currency translation adjustment	(335)	(0)
Remeasurements of defined benefit plans, net of tax	(24)	(33)
Total other comprehensive income	(315)	(28)
Comprehensive income	2,664	1,096
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,664	1,096
Comprehensive income attributable to non-controlling interests	-	-

3) Notes to Semi-annual Consolidated Financial Statements

(Notes on going concern assumption)

Not applicable.

(Notes in case of significant changes in shareholders' equity)

Not applicable.

(Accounting methods adopted particularly for the preparation of semi-annual consolidated financial statements)

(Tax expense calculation)

Tax expenses on profit before income taxes are calculated by multiplying profit before income taxes by the reasonably estimated effective tax rate for the consolidated fiscal year including the semi-annual of the consolidated accounting period under review after applying tax effect accounting.